Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zain Ul Abideen, Muhammad H Waseem, Areeba Shoaib et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of lorundrostat in adults with uncontrolled or treatment-resistant hypertension. Analyzing data from 3 randomized controlled trials involving 1165 patients on lorundrostat and 403 on placebo, the study found a significant reduction in systolic blood pressure (MD: -8.00) and diastolic blood pressure (MD: -3.31) with lorundrostat, but also an increased incidence of adverse events.
Key findings
- Lorundrostat reduced systolic blood pressure by 8.00 mmHg (MD: -8.00; P < 0.00001).
- Diastolic blood pressure decreased by 3.31 mmHg with lorundrostat (MD: -3.31; P = 0.004).
- The incidence of adverse events was higher with lorundrostat (RR: 1.47; P < 0.00001).
- Hyperkalemia occurred more frequently with lorundrostat (RR: 9.17; P = 0.002).
Why it matters
The findings highlight the potential of lorundrostat as a treatment option for patients with difficult-to-control hypertension, but also underscore the importance of monitoring for adverse effects, particularly hyperkalemia and symptomatic hypotension.